| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690434 | Urology | 2017 | 27 Pages |
Abstract
ASP3652 was generally safe and well-tolerated. It did not show efficacy on pain symptoms in patients with CP/CPPS. However, the results indicate that FAAH inhibition may attenuate lower urinary tract symptoms. Dedicated studies in patients with lower urinary tract dysfunction are needed to confirm this.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Florian M.E. Wagenlehner, J.W. Olivier van Till, Jos G.A. Houbiers, Reynaldo V. Martina, Dirk P. Cerneus, Joost H.J.M. Melis, Antoni Majek, Egils Vjaters, Michael Urban, Henrikas Ramonas, Daniel A. Shoskes, J. Curtis Nickel,